HCR 577 Current Trends and Issues in the Conduct of Global Clinical Trials
HCR 577 Current Trends and Issues in the Conduct of Global Clinical Trials
Abstract
Access to medicine is a global health challenge. Biologics are becoming more widely accessible to enhance lives and save lives, but many people still don’t have access to essential medicines because of price, market barriers and lack of equitable access. And biosimilars are creating new opportunities for improved affordability and access. Biosimilars are medicines that are very similar to biologic medicines and are equally safe and effective. Their increasing use is also having an impact on global clinical trials, manufacturing and regulations. Ahmadiani and Nikfar (2016) found that access to medicines is linked to the right to health, but developing countries lack access because of cost and regulatory issues. Alamchandani et al. (2014) explained that biosimilars may be cheaper, but require regulation with pharmacovigilance since biologics are complex. In addition, Karamehic et al. (2013) noted the pharmaceutical industry is shifting as patents expire and competition from generics and biosimilars increases.
This article explores the current trend in access to medicines with the increase in biosimilars. This paper explores the significance of this topic to international clinical trials and markets. It also considers legal issues, including patent protection and substitution laws, and regulatory frameworks which impact market access. Also discussed are special concerns such as safety, traceability and equity. Lastly, the paper offers recommendations for achieving better global access while safeguarding innovation and patient safety. Biosimilars are a promising future, but it requires careful policy, robust regulations and global collaboration.
Current Trends and Issues in the Conduct of Global Clinical Trials
Introduction
Medicine accessibility is a worldwide issue. Medicines are available, but they are costly. This is especially true when it comes to biologic medicines, like those used to treat cancer, diabetes, rheumatic disease and other conditions. There is growing interest in biosimilars as they can help drive down the cost of medicines and increase access. Their development is a significant global trend in clinical trials, manufacturing and policy.
Trend/Issue and Relevance to Current Industry Issues
Biologics are complex products originating from living cells. They are commonly used for disease treatment, but they are costly to develop and produce. Biologics are now a significant part of pharmacotherapy in particular areas where medical needs have not previously been met (Alamchandani et al. 2014). But they are costly for patients. Ahmadiani and Nikfar (2016) reported that more than two billion people worldwide did not have sufficient access to essential medicines. This indicates innovation without affordability cannot meet health needs.
Biosimilars are similar versions of licensed biologics. They are not exact copies like generic drugs because biologics are complex molecules. But they can be similarly effective and less expensive. With the patents on many biologics running out, biosimilars are bringing more competition to the global market.
This is important to global clinical trials. Comparative studies are required by sponsors to establish biosimilarity in quality, safety and efficacy. It is important to pharmaceutical manufacturing because biosimilars involve complex manufacturing, quality assurance and cold-chain distribution. Moreover, biosimilars are changing business strategies as firms shift from dependency on branded, blockbuster drugs (Karamehic, et al, 2013).
Legal Issues
A key legal issue relates to intellectual property protection. Patents provide companies with exclusive rights for a certain period, enabling them to recoup research costs. But they can slow the availability of cheaper alternatives. Ahmadiani and Nikfar (2016) described how treaties like TRIPS posed problems in some countries by discouraging the production of generic or low-cost drugs during the patent period.
The second legal issue is interchangeability. Since biosimilars are not identical to the originator biologics, in certain parts of the world, special approval is required for pharmacists to interchange biosimilars. Alamchandani et al. (2014) recommended that automatic substitution should be done with caution due to traceability and safety monitoring issues.
Liability is another issue. In the event of adverse reactions, regulators and manufacturers need to know which drug was administered. This creates the need for strong naming systems and accurate records.
Policies and Laws
Many countries have regulations for biosimilars. The European Medicines Agency was the first to establish regulations for biosimilars. The U.S. Food and Drug Administration (FDA) then developed pathways to demonstrate that the biosimilar is highly similar to the reference product without clinically relevant differences (Alamchandani et al., 2014).
These laws seek to promote innovation and reduce costs. Patent policies incentivise innovation, and biosimilar policies encourage competition following exclusivity. Government policies for reimbursement, tendering and price reform also promote biosimilar adoption (Calo-Fernández & Martínez-Hurtado, 2012).
Global agencies like the World Health Organization promote access to essential medicines and standards. Consistent global standards can support manufacturers in accessing different markets.
Special Considerations
Safety is the number one priority. Biologics are complex drugs, and small variations in manufacturing can alter the drug’s quality or lead to an immune response. So biosimilars need to be rigorously assessed and have appropriate pharmacovigilance plans. Alamchandani and colleagues (2014) identified the need for the early detection of adverse events and ensuring these are appropriately linked to the manufacturer to ensure action is taken.
Equality of health care is another factor (Narayana et al., 2012). Low- and middle-income countries often have the greatest need for health care, but cannot afford expensive treatments. Biosimilar use can help to address this. Education is also necessary. Biosimilars can be viewed with suspicion by health-care providers and patients (Piantadosi, 2024). Regulators can boost confidence with clear evidence and information.
Recommendations
First, nations should increase access to biosimilars while ensuring quality. More streamlined and efficient approval processes do not have to compromise safety if rigorous science is maintained. Faster approvals can lead to more competition and more choices for patients (Jin et al., 2022).
Second, countries should increase affordability by setting up better reimbursement, appropriate pricing and procurement. This can promote greater uptake of biosimilars, reduce the cost of health care, and improve access to medicines (Skivington et al., 2021).
Third, health systems and regulators need to prioritise pharmacovigilance and education. Pharmacovigilance is the process by which post-market adverse events are identified, reported and managed (Sharma et al., 2025). Medicine naming conventions are also crucial as they identify the medication causing the reaction. Similarly, education of health care providers and patients can increase confidence and enhance appropriate use. This can make a huge difference to consumer safety and therapeutic outcomes.
Conclusion
Easy access to biosimilars and medicines is a global health challenge. Biologics can help patients, but are expensive. Biosimilars can help improve access and reduce costs. But this requires a balanced legislative framework, good regulation and vigilance. Biosimilars can support a more equal future through global cooperation.
References
Ahmadiani, S., & Nikfar, S. (2016). Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective. DARU Journal of Pharmaceutical Sciences, 24(1), 13.
Calo-Fernández, B., & Martínez-Hurtado, J. L. (2012). Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals, 5(12), 1393-1408.
Jin, X., Chandramouli, C., Allocco, B., Gong, E., Lam, C. S., & Yan, L. L. (2020). Women’s participation in cardiovascular clinical trials from 2010 to 2017. Circulation, 141(7), 540-548.
Juhn, Y., & Liu, H. (2020). Artificial intelligence approaches using natural language processing to advance EHR-based clinical research. Journal of Allergy and Clinical Immunology, 145(2), 463-469.
Karamehic, J., Ridic, O., Ridic, G., Jukic, T., Coric, J., Subasic, D., … & Masic, I. (2013). Financial aspects and the future of the pharmaceutical industry in the United States of America. Materia socio-medica, 25(4), 286.
Narayana, S. A., Pati, R. K., & Vrat, P. (2012). Research on management issues in the pharmaceutical industry: a literature review. International Journal of Pharmaceutical and Healthcare Marketing, 6(4), 351-375.
Piantadosi, S. (2024). Clinical trials: a methodologic perspective. John Wiley & Sons.
Sattigeri, B., Alamchandani, R. R., & Karelia, P. S. (2014). Biologics and biosimilars: Role in modern pharmacotherapy and importance of pharmacovigilance. International Journal of Research in Medical Sciences, Alamchandani RR et al. Int J Res Med Sci, 2(2), 382-386.
Sharma, M., Grover, M., Suryavanshi, S. J., Sharma, N., & Shukla, V. K. (2025). Comparative Review of Clinical Trial Regulations in Different Countries: Current Scenario and Future Prospect. Reviews on Recent Clinical Trials.
Skivington, K., Matthews, L., Simpson, S. A., Craig, P., Baird, J., Blazeby, J. M., … & Moore, L. (2021). A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. bmj, 374.
HCR 577 Current Trends and Issues in the Conduct of Global Clinical Trials
